Grégory Ninot1,2,*, Estelle Guerdoux1,2, François Carbonnel1, Kerstin Faravel2, Ludovic Ismael1, Fanny Leenhardt2, Béatrice Lognos1, Caroline Perrier2, Laurent Philibert2, Boris Tronc1, Marie Viala2
Oncologie, Vol.24, No.4, pp. 605-612, 2022, DOI:10.32604/oncologie.2022.024558
Abstract A retrospective observational study carried out in the United States showed a decrease in survival in patients treated for breast, prostate, lung and colorectal cancer with complementary medicines. We verified this result with a
French population of consecutive 636 patients diagnosed with the same cancer and treated with oral chemotherapy in an hospital for three years. An interview by a pharmacist before the administration of oral chemotherapy
was made to identify the complementary medicines used by the patients. We compared the overall survival
using a log-rank test by stratifying the groups (number of cancers, number of comorbidities, age, sex). The… More >